Semaglutide

Semaglutide, sold under the brand names Ozempic, Wegovy and Rybelsus, is an antidiabetic medication used for the treatment of type 2 diabetes and an anti-obesity medication used for long-term weight management, developed by Novo Nordisk in 2012.Semaglutide is a GLP-1 receptor agonist, meaning that it mimics the action of the human incretin glucagon-like peptide-1 (GLP-1), thereby increasing insulin secretion and increasing blood sugar disposal and improving glycemic control.

Read more in the app

Semaglutide May Reverse Damage Caused by Osteoarthritis, Study Suggests

Why Scientists Are Urging Caution About a Common Ingredient in Semaglutide and Ozempic

Doctors Surprised by Semaglutide’s Heart-Saving Effect

Semaglutide and hospitalizations in patients with obesity and established cardiovascular disease - EurekAlert!

GLP-1 medicines semaglutide and tirzepatide reduce the risk of heart failure hospitalization and death by over 40% in patients with heart failure with preserved ejection fraction finds this new study in JAMA

New evidence shows tirzepatide and semaglutide strongly protect the heart

Obesity drugs improve heart health: Study shows additional benefits of semaglutide and tirzepatide - EurekAlert!

The Lancet: Study confirms cardiovascular benefits of semaglutide beyond weight loss - EurekAlert!

Liraglutide vs semaglutide vs dulaglutide in veterans with type 2 diabetes - EurekAlert!

Nearly 20% Weight Loss Achieved With Higher Dose of Semaglutide, Study Finds

Semaglutide may silence the food noise in your head

Taking semaglutide turns down food noise, research suggests - EurekAlert!

The Lancet Diabetes & Endocrinology: Higher doses of semaglutide can safely enhance weight loss and improve health for adults living with obesity, two new clinical trials confirm - EurekAlert!

Semaglutide reduces cocaine use in rats - EurekAlert!

Semaglutide and tirzepatide in patients with heart failure with preserved ejection fraction - EurekAlert!

Ocular adverse events with semaglutide - EurekAlert!

Semaglutide or tirzepatide and optic nerve and visual pathway disorders in type 2 diabetes - EurekAlert!

Changes in cardiovascular risk factors and health care expenditures among patients prescribed semaglutide - EurekAlert!

Semaglutide Demonstrates Impressive Heart Benefits – Even Before You Lose Weight

Tirzepatide vs. Semaglutide: New Research Reveals Surprising Metabolic Differences